Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Work In Process: 2023-2024

Historic Work In Process for Tarsus Pharmaceuticals (TARS) over the last 2 years, with Dec 2024 value amounting to $614,000.

  • Tarsus Pharmaceuticals' Work In Process fell 37.12% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 37.12%. This contributed to the annual value of $614,000 for FY2024, which is 56.63% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Work In Process of $614,000 as of FY2024, which was up 56.63% from $392,000 recorded in FY2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Work In Process peaked at $614,000 during FY2024, and registered a low of $392,000 during FY2023.
  • Over the past 2 years, Tarsus Pharmaceuticals' median Work In Process value was $503,000 (recorded in 2023), while the average stood at $503,000.
  • Data for Tarsus Pharmaceuticals' Work In Process shows a peak YoY surged of 56.63% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Tarsus Pharmaceuticals' Work In Process stood at $392,000 in 2023, then soared by 56.63% to $614,000 in 2024.